Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
A neuron-specific protein disposal mechanism called the membranal proteasome has been identified as a key player in tau aggregation and Alzheimer's pathology. This finding reframes neurodegeneration not as a mutation problem but as a failure in cellular quality control, with direct implications for how protein misfolding accumulates in the aging brain.
Environmental chemical exposures—the exposome—now explain mortality variation better than genetics, yet remain largely unmeasured in population health studies. Systematic quantification of synthetic chemicals in biobank samples could identify disease drivers and inform large-scale risk reduction.
Longeveron is advancing laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young donor bone marrow, across four clinical indications including hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's licensing strategy at BIO 2026 signals movement toward commercialization of a cellular therapy platform with demonstrated efficacy signals across multiple disease states.
Surgery impairs memory and brain cell regeneration in aged mice by disrupting cholinergic signaling from the medial septum to the hippocampus. Restoring this pathway through pharmacological or sustained neural activation reverses both cognitive and neurogenic deficits, suggesting a tractable mechanism for postoperative cognitive dysfunction.
Intranasal Protollin, a pathogen-associated molecular pattern (PAMP), shifts immune activation in early Alzheimer's disease by enhancing monocyte phagocytosis while reducing CD8+ T cell cytotoxicity in a Phase 1 trial. This immune recalibration addresses a core driver of neuroinflammation implicated in cognitive decline.
Montara Therapeutics is developing a brain-selective approach to mTOR inhibition that targets alpha-synuclein accumulation in Parkinson's disease while avoiding systemic side effects. The strategy uses a proprietary peripheral blocker to confine therapeutic activity to the central nervous system, addressing a longstanding limitation that has prevented effective translation of mTOR-targeting compounds into neurological treatments.
Cortechs.ai and Microsoft have integrated quantitative imaging and AI-driven biomarkers into PowerScribe One, automating volumetric measurements and report generation for neurodegenerative disease, neuro-oncology, traumatic brain injury, and prostate assessment. This workflow automation reduces manual entry and accelerates clinical decision-making in radiology.
Niagen Bioscience renamed its research program to align with company branding while expanding support for NAD+ science across 300+ collaborations and 45+ peer-reviewed human studies. The initiative now prioritizes clinical investigation into energy metabolism, cognitive function, cardiovascular health, and immune response through both oral and pharmaceutical-grade formulations.
Extended wearable monitoring in older adults demonstrates feasibility for detecting falls and near-falls in real-world settings, revealing both the practical potential and usability constraints of sustained device wear. Understanding which older adults benefit most from continuous monitoring and how to design systems they will actually use determines whether this technology translates into reduced fall risk and improved longevity outcomes.
Social participation patterns in older adults show measurable associations with cognitive trajectory, with the balance between family-centered and broader community engagement emerging as a critical variable. This finding positions social structure and relational patterns as modifiable factors in cognitive resilience during aging.
A strategic partnership between Deep Science Ventures and Medicines Discovery Catapult targets the blood-brain barrier as a systemic bottleneck limiting neurological drug delivery. Over 40% of the global population faces neurological conditions, yet the ability to transport therapeutics across this selective barrier remains the primary constraint, not the therapeutic discovery itself.